Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology TherapeuticsBOSTON & SOUTH SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II (“Helix”) (Nasdaq: HLXB), a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) (“BBOT”), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, today announced that Helix retained approximately $120 million in its trust account, net of redemptions by public shareholders, representing more than 60% of the cash held in trust. The deadline for submitting redemption requests was July 31, 2025.
Helix Acquisition Corp. II Announces Closing of $184 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares
Helix Acquisition Corp. II (Nasdaq: HLXB) (the “Company”) announced today that on February 13, 2024 it closed the initial public offering of 18,400,000 Class A ordinary shares which includes 2,400,000 shares issued pursuant to the full exercise by the underwriter of its over-allotment option. The offering was priced at $10.00 per share resulting in gross proceeds of $184,000,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
Helix Acquisition Corp. II Announces Pricing of Upsized $160 Million Initial Public Offering
Helix Acquisition Corp. II (the “Company”) announced today that it priced its upsized initial public offering of 16,000,000 Class A ordinary shares at $10.00 per share. The shares will be listed on The Nasdaq Global Market and trade under the ticker symbol “HLXB” beginning today. The Company expects the offering to be consummated on February 13, 2024.
